NCT06553547View on ClinicalTrials.gov

4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs

PHASE2RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

July 24, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Irritable Bowel Syndrome with Constipation (IBS-C)
Interventions
DRUG

Tenapanor

Tenapanor 5 mg/mL solution

DRUG

Placebo

Matching Placebo solution

Trial Locations (2)

33143

RECRUITING

Florida Pharmaceutical Research and Associates, Inc., South Miami

78550

RECRUITING

Texas Digestive Specialists, Harlingen

Sponsors

Lead Sponsor

Ardelyx
All Listed Sponsors
lead

Ardelyx

INDUSTRY

NCT06553547 - 4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs | Biotech Hunter | Biotech Hunter